Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo

Background: Docetaxel and doxorubicin combination has been widely used in anaplastic thyroid cancer/ATC treatment but often results in serious adverse effects and drug resistance. Resveratrol effectively inhibits ATC cell proliferation in vitro without affecting the corresponding normal cells, while...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Le, Lin, Xiao-Min, Nie, Jun-Hua, Ye, Hai-Shan, Liu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806457/
https://www.ncbi.nlm.nih.gov/pubmed/33457193
http://dx.doi.org/10.7150/ntno.53844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806457/
https://www.ncbi.nlm.nih.gov/pubmed/33457193
http://dx.doi.org/10.7150/ntno.53844

Ejemplares similares